Replies to post #113670 on Biotech Values

[DewDiligence]

ZMH (63.71) at highest price since Lehman bankruptcy. This is notable given the substantial headwinds faced by medical-device companies from a slowdown in elective procedures and reimbursement cuts in Europe.